Subsection
Metabolic & Diabetes Lifestyle Support sits under Chronic Condition Management . Glucose control, insulin resistance, and day-to-day metabolic management.
3 stories
SGLT2 inhibitors like empagliflozin and dapagliflozin started as diabetes drugs but now protect heart and kidney function. We explain how they work, who benefits, and the side effects to know.
A 2026 analysis says CGMs may complement standard tests for prediabetes detection. Here is who actually benefits from wearing one, what it shows, and what it cannot tell you.
FDA enforcement ended the routine compounding of semaglutide and tirzepatide in 2026. If your cheap telehealth GLP-1 just stopped refilling, here is a safe path to a legal alternative.
More from Chronic Condition Management .
